AI/ML Connected Medical Devices: Cybersecurity Regulatory Requirements You Cannot Afford to Ignore

Why Cybersecurity for AI/ML Devices Is a Different Problem Entirely

If your medical device uses an AI or machine learning algorithm and connects to a network, cloud platform, or external system, you are not dealing with a standard cybersecurity challenge. You are dealing with a layered risk environment where the attack surface shifts continuously, the decision-making logic can be influenced by adversarial inputs, and the regulatory expectations are evolving faster than most quality systems can track.

FDA has made its position clear: cybersecurity is a patient safety issue, not an IT issue. For AI/ML-enabled connected devices, that statement carries even more weight. A compromised algorithm or manipulated data pipeline does not just expose patient records. It can silently degrade clinical performance, corrupt training feedback loops, or cause the device to make decisions it was never validated to make.

This post breaks down the specific cybersecurity considerations your team needs to address during device development, premarket submission, and post-market surveillance -- before FDA raises them for you.

The Regulatory Framework You Need to Understand

FDA consolidated its cybersecurity expectations in the final guidance document Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions, released in September 2023. This guidance applies to any device with cybersecurity risk, but its implications are especially significant for AI/ML-enabled connected products.

The guidance aligns with the requirements introduced under Section 524B of the FD&C Act, added by the Consolidated Appropriations Act of 2023, which gives FDA explicit statutory authority to require cybersecurity information in premarket submissions and to refuse acceptance of submissions that do not meet those requirements. This is not soft guidance. Non-compliance is now a legitimate reason for a Refuse to Accept determination.

For AI/ML software as a medical device (SaMD) specifically, you also need to read the 2021 action plan for AI/ML-based SaMD and FDA's proposed regulatory framework alongside the cybersecurity guidance. These documents together define what FDA expects from devices whose logic can change over time.

Specific Cybersecurity Risks Unique to AI/ML Connected Devices

Adversarial Machine Learning Attacks

AI models are vulnerable to inputs that are specifically crafted to manipulate outputs. An adversary does not need to breach your server. They may only need to manipulate sensor data, imaging inputs, or network payloads in ways that cause your model to produce dangerous outputs while appearing to function normally. Your threat model must account for this class of attack explicitly.

Model Integrity and Supply Chain Risk

FDA's 2023 cybersecurity guidance requires a Software Bill of Materials (SBOM) for all devices with software. For AI/ML devices, this must extend to pre-trained model components, third-party datasets used in training, and any cloud-based inference services your device depends on. If your model relies on a third-party API or hosted service, a supply chain compromise in that dependency becomes your patient safety problem.

Continuous Learning and Post-Deployment Drift

Devices that use adaptive algorithms or that are updated based on real-world performance introduce a unique post-market cybersecurity vector. If an attacker can influence the data being fed back into a retraining pipeline, they can gradually degrade the model's performance in ways that are difficult to detect. Your post-market surveillance plan, required under 21 CFR Part 820 and FDA's Quality System Regulation, must explicitly address algorithm monitoring and anomaly detection in production environments.

What FDA Expects in Your Premarket Submission

Whether you are filing a 510(k), De Novo request, or PMA, FDA expects a cybersecurity section that addresses the following for AI/ML connected devices:

• Threat modeling documentation that identifies realistic attack scenarios specific to AI/ML components, not just generic network threats
• Security architecture diagrams showing data flows between the device, cloud, and external systems, including where model inference occurs
• A Software Bill of Materials (SBOM) covering all software components including AI/ML frameworks, libraries, and dependencies
• A vulnerability disclosure policy and a coordinated vulnerability disclosure process that meets FDA expectations under Section 524B
• A Total Product Lifecycle (TPLC) approach demonstrating how cybersecurity risks will be monitored and addressed post-clearance

FDA reviewers are increasingly sophisticated. A generic cybersecurity risk assessment that does not address AI/ML-specific vectors will generate additional information requests and delay your clearance timeline.

Post-Market Obligations Are Not Optional

Under 21 CFR Part 806 and FDA's post-market guidance, manufacturers have ongoing obligations to monitor, report, and remediate cybersecurity vulnerabilities. For AI/ML devices, this means establishing real-time monitoring of model performance metrics as a patient safety function, not just a product improvement exercise. Significant performance degradation caused by adversarial manipulation may constitute a reportable event under 21 CFR Part 803.

Your quality management system, whether certified to ISO 13485 or compliant with FDA's QSR under Part 820, must be updated to reflect these responsibilities with clear owners, escalation paths, and documented procedures.

Build Cybersecurity In, Not On

The single most common and costly mistake ADB Consulting sees in AI/ML device programs is treating cybersecurity as a documentation exercise rather than a design discipline. By the time you are preparing your premarket submission, your architecture is largely fixed. If cybersecurity was not considered during system design, you may find yourself facing significant re-architecture, re-validation, and re-testing -- at exactly the point in development when time and budget are most constrained.

Start your threat modeling at the design input phase. Make cybersecurity a standing agenda item in your design reviews. Require your AI/ML vendor or development team to produce an SBOM from the beginning of the project, not at the end.

Ready to Get Your AI/ML Device Submission Cybersecurity-Ready?

At ADB Consulting and CRO Inc., we work directly with medical device founders and regulatory teams to build cybersecurity strategies that satisfy FDA reviewers and protect patients. We know what FDA is looking for because we have spent years helping companies navigate exactly these submissions.

If your AI/ML connected device program needs a cybersecurity regulatory review, a gap assessment against FDA's 2023 guidance, or help building a submission-ready cybersecurity package, book a free discovery call with Andre Butler today at adbccro.com. Let's make sure your device reaches patients -- on schedule and without a cybersecurity-related hold.

If this applies to your program, our 524B Cybersecurity Gap Assessment walks through the process in detail.